Perspective Therapeutics develops a proprietary class of theranostics that utilize radiation and radiopharmaceuticals to target tumors directly, enhancing treatment efficacy while minimizing damage to healthy tissues. This approach addresses the limitations of traditional cancer therapies by delivering precise medical doses to the tumor site, improving patient outcomes.
Funding
$80M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional cancer therapies often lack precision, leading to damage of healthy tissues and reduced efficacy due to non-specific targeting of tumors. This can result in significant side effects and limit the effectiveness of treatment, especially in metastatic or unresectable cancers.
Solution
Perspective Therapeutics is developing a class of theranostics that utilize targeted radiation to treat cancers. Their approach involves using radiopharmaceuticals carrying isotopes like Lead-212 (212 Pb) to deliver radiation directly to tumor cells, minimizing damage to surrounding healthy tissue. By targeting specific receptors on cancer cells, Perspective's theranostics aim to improve treatment efficacy and reduce toxicity compared to traditional radiation therapies. The company is also developing imaging diagnostics using the same targeting peptides, enabling personalized treatment strategies.
Target Audience
The primary target audience includes patients with metastatic or unresectable cancers, particularly neuroendocrine tumors and melanoma, as well as the clinicians who treat them.
Features
- Utilizes alpha-emitting isotope Lead-212 (212 Pb) for targeted radiation therapy.
- Employs proprietary targeting peptides to selectively bind to cancer cells.
- Offers a theranostic approach, combining targeted therapy with companion imaging diagnostics.
- VMT-α-NET program targets somatostatin receptor subtype 2 (SSTR2) expressing neuroendocrine tumors (NETs).
- PSV359, a molecule targeting fibroblast activation protein-α (FAP-α), is in development for various solid tumors.
- Proprietary lead-specific chelator (PSC) binds 203 Pb for SPECT imaging and 212 Pb for alpha particle therapy.
- Investigational New Drug (IND) application planned for PSV359 by the end of 2024.